Community Search
Pre-congress Courses

There is no additional cost to attend pre-congress sessions. No sign up required. Open to all delegates.

Pre-congress Course I:   Fundamentals of PD (Simultaneous translation into French)

Pre-congress Course II:  Interdisciplinary Care & Parkinson's Disease

Pre-congress Course III: Science & Advocacy
(Note: Each session in Course III is supported independently by the sponsor(s) of the session.) 

Download the full Pre-congress program


Tuesday, October 1, 2013

Pre-congress Course I : Fundamentals of PD [Room 517D]

Target Audience:
Non-clinicians, people with Parkinson’s, others

Goal: Expose participants to key topics that will be elaborated on in the program. Give them a glimpse of what is to come and tools to get the most out of the meeting. Introduce the role of PwPs into the meeting design and success as well as the legacy of the WPC.

Learning objectives:

  1. To gain a basic understanding of Parkinson’s, including the research into the cause(s) of the disease, symptoms, and therapies;
  2. To learn the spectrum of care and rehabilitation options once diagnosed with Parkinson’s;
  3. To understand future therapies for Parkinson’s.


9:15AM  Introduction                                                                  Tom Isaacs (UK)

9:30AM  What is PD?                                                                  Stanley Fahn (USA)

9:45AM  Pathology of PD                                                           Dennis Dickson (USA)

10:00AM What causes PD?                                                      Marie-Francoise Chesselet (USA)

10:15AM Q & A Panel                                                                Facilitator: David Iverson (USA)


11:00AM Non-motor features                                                    Ronald Pfeiffer (USA)

11:15AM Medical therapy                                                         Christopher Goetz (USA)

11:30AM Surgical therapy                                                         Andres Lozano (Canada)

11:45AM Q & A Panel                                                                Facilitator: David Iverson (USA)


1:15PM  What you can do after you are diagnosed to stay involved       Peter Davison (Canada)

1:30PM Therapeutic options to stay active and involved

  • Speech and Parkinson’s                                                Bonnie Bereskin (Canada)
  • Physical therapy and Parkinson’s                                Terry Ellis (USA)
  • Occupational therapy and Parkinson’s                        Margarita Makoutonina (Australia)

2:15PM Q & A Panel                                                                 Facilitator: Linda Morgan (USA)


3:00PM Future therapies

  • Stem cells                                                                      Patrik Brundin (USA)
  • Viral vectors and gene therapy                                  Stephane Palfi (France)
  • Drug treatments                                                           Olivier Rascol (France)

3:50PM Q & A Panel                                                                 Facilitator: Linda Morgan (USA)

3:55PM Getting the most out of the WPC 2013                    Bob Kuhn (Canada)

4:05 PM Wrap-up                                                                     Bob Kuhn (Canada) & Stanley Fahn (USA) 

6:30 PM Opening Ceremony (Hall 517ABC)

7:30 PM Welcome Reception
(Exhibit Hall, 2nd Floor)


Pre-congress Course II : Interdisciplinary Care & Parkinson’s Disease [Room 518ABC]

Target Audience:
Allied health professionals, members of multidisciplinary teams, health professionals interested in interdisciplinary care models

Goal: The aim of this pre-congress course is to provide a forum for discussion of service delivery models in PD. Current model types will be presented for the purpose of discussion and will be referenced to a template of current service delivery components. The ideal model should focus on the complexity of PD, the need to provide continuity of care and be able to deal with the cumulative morbidities associated with a chronic illness.

Learning objectives:

  1. Understand the complexity of PD and its underlying pathological basis;
  2. Be aware of the wide variety of factors that need to be considered in providing comprehensive and continuous care;
  3. Be able to advise on the development, modification or redesign of a service model for PD taking into consideration the organizational infrastructure of the delegate’s institution.

9:00AM Introduction                                                                    Anne-Louise Lafontaine (Canada)

9:10AM What do we face?                                                          Bastiaan Bloem (Netherlands)

9:40AM How is it addressed? & Overview
of available delivery options & models currently in use              Ruth Hagestuen (USA)

10:10AM What this all means for people with Parkinson’s         Alice Templin (Canada)


11:00AM    Introduction                                                          Mark Guttman (Canada) 

The role of the Multidisciplinary Team: Evidence that shows
it is working and what UNIQUE contribution these people make to the team.


11:20AM General practitioner’s role                                      Christiane Lepage (Canada)

11:40AM Geriatrician’s role                                                     Peter Fletcher (UK)

12:00PM Nurse’s role                                                               Lucie Lachance (Canada)

12:20PM Rehabilitation team’s role                                          TBD

12:40PM - 1:10PM  Q&A                                                        Facilitator: Mark Guttman (Canada)

1:10PM – 2:10PM LUNCH

2:10PM PANEL - Multidisciplinary teams                                Introduction: Ruth Hagestuen (USA)
How are these approaches and models different?
What strengths do they offer or weakness do they create?
How do each of these models solve the problem of an individualized approach to care? Or do they?
[20 minute talk + Q&A immediately following each talk]

  • 2:15PM Israeli Model - Tel Aviv                                                     Nir Giladi (Israel)
  • 2:45PM Netherlands Model – ParkinsonNet                                  Marten Munneke (Netherlands)
  • 3:15PM US Model - Struthers Center                                            Ruth Hagestuen (USA)
  • 3:45PM Australian Model                                                               TBD
  • 4:15PM Canadian Model - McGill Movement Disorders Clinic    Anne-Louise Lafontaine (Canada)

4:45PM - 5:10PM Q&A from all panelists & audience         Bastiaan Bloem, (Netherlands) & Peter Fletcher (UK)

5:10PM - 5:30PM Wrap-up                                                     Alice Templin (Canada) & Nir Giladi (Israel)

6:30 PM Opening Ceremony (Hall 517ABC)

7:30 PM Welcome Reception
(Exhibit Hall, 2nd Floor)


Pre-congress Course III : Science & Advocacy [Room 516ABCD]

Note: Each session in Course III is supported independently by the sponsor of the session.  

Target Audience:
These will be crosstalk sessions appropriate for a mix of the community, including clinicians, researchers, people with Parkinson’s and others.

8:30 AM - 10 AM  –         Chelsea Therapeutics, Impax Pharmaceuticals, Neurodyn, & Depomed, Inc.
10 AM – 10:30AM –        Coffee break

10:30 AM-11:30 AM –     GE Healthcare

11:45 AM – 12:45PM –    Medtronic

12:45 PM – 1:45 PM –     LUNCH

1:45 PM – 3 PM –           TEVA Pharmaceuticals
3 PM – 3:30 PM –           Coffee break

3:30 PM – 4:30 PM –      Parkinson's Disease Foundation

4:45 PM – 5:45 PM –      Michael J. Fox Foundation for Parkinson's Research

6:30PM – 7:30 PM
      Opening Ceremony in Room 517ABC
7:30PM - 9:30 PM
       Welcome Reception in Exhibit Hall on 2nd floor


 8:30 AM - 10 AM            


Panel on new science and ongoing research: What's in the pipeline?
Rajesh Pahwa (USA)

Panelist #1: Enhancing norepinephrine neurotransmission as a promising therapeutic target – Peter LeWitt (USA)
Panelist #2: Use of new levodopa preparations for reducing OFF time
Rajesh Pahwa (USA)
Panelist #3:
Novel delivery approaches -  Leonard Verhagen (USA) 
Panelist #4:
Natural products in the development of new therapies – H.A. Robertson (Canada)
Learning objectives:
1. To understand newer forms of newer forms of levodopa preparations to reduce off time;
2. Understand products related to improving orthostatic hypotensive symptoms;  
3. Use of natural products in developing new therapies.

Supported through unrestricted educational grants from Chelsea Therapeutics, Impax Pharmceuticals, Neurodyn, and Depomed, Inc.


10 AM- 10:30 AM               Coffee break

10:30 AM – 11:30 PM

Role of imaging in diagnosis and as a window into progression and pathogenesis of Parkinson’s disease?

Moderator: Oksana Suchowersky (Canada)

Talk #1: Imaging Approaches – Nicola Pavese (UK)

Talk #2: Clinical Implications of Imaging – Ken Marek (US)

Learning objectives:

1. To understand the role imaging plays in diagnosis of Parkinson’s;

2. Be able to explain how imaging is used to follow progression of Parkinson’s;

3. Understand how imaging is used to study the pathogenesis of Parkinson’s.

Supported through and unrestricted educational grant from GE Healthcare.


11:45 AM – 12:45 PM


Role of Deep Brain Stimulation in Management of Parkinson's Disease

Moderator: Joseph Jankovic (USA)

Talk #1: Rationale and clinical outcomes of DBS in patients with advanced PD – Michael Okun (USA) 

Talk #2: DBS for early fluctuating disease and controversial indications - Günther Deuschl (Germany)

Learning objectives:
1. To understand the rationale and patient selection for DBS;
2. To learn about the benefits and the risks of DBS;
3. To interpret data from trials of clinical outcomes of DBS.

Supported through and unrestricted educational grant from Medtronic


1:45 PM – 3 PM

Attempts to obtain neuroprotection in PD

Moderator: Eduardo Tolosa (Spain)
Talk#1: Status of current therapies – Fabrizio Stocchi (Italy)

Talk#2: Novel targets and candidate approaches – Patrik Brundin (USA)

Talk#3: Obstacles to developing a neuroprotective therapy – Warren Olanow (USA)

Learning objectives

1. To understand current unmet needs;

2. To be able to define targets for putative neuroprotective therapies;
3. To appreciate the obstacles that must be overcome in order to develop a neuroprotective therapy.


Supported through an unrestricted educational grant from Teva Pharmaceuticals

3:30 PM - 4:30 PM

Patient Engagement in Research - The Next Blockbuster Drug?

Moderator: Ronnie Todaro (USA)

Panelists: Diane Cook (USA), Michael Schwarzschild (USA), Stephen Samis (Canada)

Learning objectives:
1.  To learn about the ongoing efforts of community members to engage people with Parkinson’s in the clinical trial process and advance research advocacy;
2. Gain an understanding of what patient engagement is, its role in research and health care decision-making as well ad model for patient engagement and outcomes;
3. Learning about the potential of patient engagement to accelerate therapies and improve health outcomes.

Supported through an unrestricted educational grant from Parkinson’s Disease Foundation

WPC Disclaimer: This session was organized by the Parkinson's Disease Foundation. The program was approved by the WPC, but topics and opinions do not necessarily reflect that of the World Parkinson Coalition.


4:45 PM – 5:45 PM


What’s taking so long, and what can we do about it?

Moderator: David Iverson

Topic: An interactive panel discussion about the most difficult challenges facing Parkinson’s research today, strategies and progress to address them, and how the community can take action to speed a cure.

Panelists: David Burn (UK), Soania Mathur (Canada), Todd Sherer (USA), David Standaert (USA), David Weiner (USA)


Learning objectives:
1. Develop familiarity with the biggest challenges faced in Parkinson’s research today;

2. Gain an understanding of strategies – and progress – in addressing these challenges in order to get to new therapies and a cure;

3. Learn about the role patients and their loved ones can – and need – to play in clinical research to speed a cure in our lifetime.

Supported through an unrestricted educational grant from The Michael J. Fox Foundation for Parkinson’s Research

WPC Disclaimer: This session was organized by the Michael J. Fox Foundation. The program was approved by the WPC, but topics and opinions do not necessarily reflect that of the World Parkinson Coalition.

6:30 PM - 7:30 PM  Opening Ceremony (Hall 517ABC)

7:30 PM - 9:30 PM  Welcome Reception
(Exhibit Hall, 2nd Floor)



Membership Management Software Powered by YourMembership  ::  Legal